Navigation Links
DURECT to Participate in Upcoming Healthcare Conferences
Date:8/21/2012

CUPERTINO, Calif., Aug. 21, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. 

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

  • Matt Hogan, Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5 at 3:15 p.m. Eastern Time.  The conference is being held at the Four Seasons Hotel in Boston.  A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2012/36113426.cfm
  • James E. Brown, President and CEO, will also present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10 at 3:40 p.m. Eastern Time.  The conference is being held at the Waldorf Astoria in New York.  A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq22/drrx.  

A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is a specialty pharmaceuticalcompany developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR, ELADUR®, and TRANSDUR®-Sufentanil.  DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.  For more information, please visit www.durect.com.

NOTE: POSIDUR, SABER, ORADUR®, TRANSDUR®, ELADUR and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.  REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.


'/>"/>
SOURCE DURECT Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
3. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
4. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
5. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
6. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
7. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
8. University of Michigans Wolverine Venture Fund Participates in $25 Million Series D Investment in Sonitus Medical
9. BlackStratus participates in Joint FDA-ISPE CGMP Conference
10. ViroPharma To Participate In The JMP Securities Healthcare Conference
11. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... Mich. , May 8, 2017  Diplomat Pharmacy, ... WRB Communications, Inc. ("WRB"), a health care service ... . WRB specializes in relationship management programs ... WRB will join ... Diplomat,s commercialization support services for manufacturers, biotech firms, and ...
(Date:5/4/2017)... MEMPHIS, Tenn. , May 4, 2017 /PRNewswire/ ... of Infection Control, Ultraviolet-C light as ... demonstrated Tru-D SmartUVC,s ability to reduce bioburden on ... influenced bioburden reduction on high-touch, complex medical equipment ... in surgical infections. "This study further ...
(Date:5/4/2017)... BOTHELL, Wash. , May 4, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... media ("BioLife" or the "Company"), today announced that ... released after market close on Thursday, May 11, 2017, ... and live webcast at 1:30 p.m. PT that afternoon. ...
Breaking Medicine Technology:
(Date:5/22/2017)... , ... May 22, 2017 , ... “Homeostasis: The Journey ... learning to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ride ... in the dead of winter and to a dark place where Donald considers suicide. ...
(Date:5/21/2017)... , ... May 19, 2017 , ... Chris Cornell, 52, was found dead on the ... one of the most respected lead singers in the rock industry would take his own ... mental illness. FindaTopDoc investigates how mental illness played a role in the death of ...
(Date:5/21/2017)... ... 21, 2017 , ... For the past 10 years, the ... policymakers, and activists wanting to address equity issues in breastfeeding, and move the ... from a recent series of from this conference. , The opening two ...
(Date:5/19/2017)... ... May 19, 2017 , ... In a continuous effort to raise awareness of ... mattress company that specializes in natural and organic latex mattresses, has announced that they ... every unique share their recent viral Facebook video receives, up to $10,000.00. ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a ... and entrepreneurs throughout the California Central Valley, is announcing a joint charity initiative with ... support for a local kid’s camp event. , The Boys and Girls Club of ...
Breaking Medicine News(10 mins):